Results 191 to 200 of about 60,176 (280)

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study

Cancer, Volume 132, Issue 10, 15 May 2026.
Momelotinib demonstrated robust real‐world activity after ruxolitinib failure, with clinically meaningful improvements in spleen (≥50% spleen length reduction, 30.0%), symptoms (≥50% total symptoms score reduction, 39.2%), and anemia (major response, 35.7%) at 6 months.
Francesca Palandri, Monia Marchetti, Elena M. Elli, Alessandro Isidori, Ilaria Gianesello, Chiara Sartor, Novella Pugliese, Maria Di Perna, Erika Morsia, Susanna Gallo, Federico Itri, Vittorio Montefusco, Elena Crisà, Annalisa Biagi, Eloise Beggiato, Olga Mulas, Giulia Benevolo, Elisabetta Abruzzese, Marco Santoro, Alessandra Iurlo, Elisabetta Calistri, Marco Rossi, Bruno Martino, Mario Tiribelli, Carmen Fava, Arbana Dizdari, Monica Crugnola, Andrea Duminuco, Amedeo Votto, Selene Guerzoni, Giovanni Caocci, Fabrizio Pane, Francesco Lanza, Filippo Branzanti, Alessandra Dedola, Flavia Salvatore, Florian H. Heidel, Massimo Breccia, Giuseppe A. Palumbo, Andrew T. Kuykendall, Alessandro Lucchesi, Sara Galimberti   +41 more
wiley   +1 more source

Administration of erythropoietin prevents bone loss in osteonecrosis of the femoral head in mice [PDF]

, 2017
Jin, Hongting, Lao, Yangjun, Mao, Qiang, Ruan, Hongfeng, Tong, Peijian, Wang, Pinger, Wu, Chengliang, Xiao, Luwei, Xu, Taotao, Zhang, Shanxing, Zhou, Li   +10 more
core   +2 more sources

Over eight years of transfusion independence with continuous erythropoietin receptor activator and Roxadustat in transfusion-dependent low-risk myelodysplastic syndrome. [PDF]

Oxf Med Case Reports
Ikenoue T, Furumatsu Y, Kitamura T.
europepmc   +1 more source

Is the erythropoietin receptor the key to the identification of the central macrophage in erythroblastic islands? [PDF]

Blood Sci, 2020
Blanc L, Mohandas N.
europepmc   +1 more source

Efficacy of continuous erythropoietin receptor activator for end-stage renal disease patients with renal anemia before and after peritoneal dialysis initiation. [PDF]

Clin Exp Nephrol, 2021
Fujimoto D, Adachi M, Miyasato Y, Hata Y, Inoue H, Oda A, Kakizoe Y, Nakagawa T, Shimasaki A, Nakamura K, Nagayoshi Y, Mukoyama M.   +11 more
europepmc   +1 more source

Statistical Discrimination of Urinary Steroid Biomarkers in the Athlete Biological Passport: A Novel Approach to an Abnormal Steroid Profile Score (ASPS)

Drug Testing and Analysis, Volume 18, Issue 5, Page 608-618, May 2026.
The study developed a single Abnormal Steroid Profile Score (ASPS) to improve interpretation of the Athlete Biological Passport steroid module. Using Bayesian modelling and logistic regression, biomarker patterns from laboratory and doping control data successfully discriminated between doped and clean individuals, with improved classification ...
James G. Hopker, Jim E. Griffin, Matthew N. Fedoruk, Laura A. Lewis   +3 more
wiley   +1 more source

Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease [PDF]

, 1999
Lang, Susanne M., Schiffl, Helmut
core   +1 more source

Evaluation of Erythropoietin and Erythropoietin Receptor Levels in Children with Autistic Spectrum Disorder: Cross-sectional Study. [PDF]

Clin Psychopharmacol Neurosci
Oner E, Kurutas EB, Altun H.
europepmc   +1 more source

Podocyte Markers as Diagnostic Biomarkers of Diabetic Nephropathy: A Case–Control Comparison to Haemato‐Biochemical Markers in a Ghanaian Population

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This study shows that urinary nephrin and related podocyte injury markers are elevated among people living with diabetes in Ghana, particularly those with macroalbuminuria. Nephrin demonstrated discriminatory ability, supporting its role as an exploratory biomarker for diabetic nephropathy rather than a standalone diagnostic tool.
Helen Owusu‐Asante, Samuel Nkansah Darko, Ebenezer Senu, Max Annani‐Akollor   +3 more
wiley   +1 more source

Trends in the Detection of Erythropoietin Receptor Agonists (ERAs) in Anti-Doping: An Analysis of Recent Adverse Analytical Findings (AAFs). [PDF]

Drug Test Anal
Equey T, Broséus J, Baume N, Aikin R.
europepmc   +1 more source